{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Hits New 52-Week High of $13.33
Amylyx Pharmaceuticals, Inc. has achieved a new 52-week high of USD 13.33, reflecting a significant increase in stock performance over the past year. The company, with a market capitalization of USD 931 million, operates in the Pharmaceuticals & Biotechnology industry and has shown resilience despite being loss-making.
Amylyx Pharmaceuticals Hits New 52-Week High of $13.09
Amylyx Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology industry, has a market capitalization of USD 931 million and continues to navigate its financial challenges while demonstrating notable growth.
Is Amylyx Pharmaceuticals, Inc. overvalued or undervalued?
As of May 8, 2025, Amylyx Pharmaceuticals is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics, including a price-to-book ratio of 2.36 and an ROE of -79.34%, while significantly underperforming its peers despite a strong one-year stock return of 182.02%.
Is Amylyx Pharmaceuticals, Inc. technically bullish or bearish?
As of June 6, 2025, the technical trend is bullish, supported by daily moving averages and a bullish weekly MACD, despite mixed signals from Bollinger Bands and a mildly bearish weekly Dow Theory.
What does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $36 million and a market cap of $475.12 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -79.34%.
How big is Amylyx Pharmaceuticals, Inc.?
As of Jun 18, Amylyx Pharmaceuticals, Inc. has a market capitalization of 475.12 million, classifying it as a Micro Cap company, with net sales of -1.27 million and a net profit of -218.86 million over the latest four quarters. Shareholder's funds are 164.76 million, and total assets are 193.63 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
